9 research firms give NuVasive a ‘buy’ rating — 3 quick notes

Nine of 13 research firms currently covering San Diego-based NuVasive believe the medical device company will continue trending upwards, according to Sports Perspective.

Advertisement

Here are three things to know:

 

1. One analyst rated the stock with a sell rating while three gave a hold rating.

 

2. The average one year price target issued by brokers who reported on the stock is $68.60.

 

3. NuVasive is a medical device company focused on creating minimally invasive spine products.

 

More device articles:

Medovex, AlfaMed, & more: 4 recent device company partnerships

Reprocessed medical devices market gaining traction — 4 observations

4 things to know about Intelligent Implant Systems

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new product launches and leadership appointments, here are seven key headlines from Stryker in the first quarter of 2026.…

  • Xtant Medical’s 2025 revenue reached $133.9 million, a 14% increase year over year, according to financial results posted March 31.…

Advertisement

Comments are closed.